Response by Zhang et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19".
作者信息
Zhang Peng, Zhu Lihua, Cai Jingjing, Lei Fang, Qin Juan-Juan, Wang Yibin, Yuan Yufeng, Rohit Loomba, Liu Peter P, Li Hongliang
机构信息
From the Department of Cardiology, Renmin Hospital of Wuhan University, China (P.Z., L.Z., J.-J.Q., H.L.).
Medical Science Research Center (P.Z., H.L.).
出版信息
Circ Res. 2020 Jun 5;126(12):e142-e143. doi: 10.1161/CIRCRESAHA.120.317242. Epub 2020 Jun 4.
Abstract
摘要
相似文献
1
Response by Zhang et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19".张等人对关于文章《住院使用血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂与 COVID-19 住院高血压患者死亡率的关联》的信件的回复
Circ Res. 2020 Jun 5;126(12):e142-e143. doi: 10.1161/CIRCRESAHA.120.317242. Epub 2020 Jun 4.
2
Response by Cohen et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19".科恩等人对关于文章《血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的住院使用与 COVID-19 住院高血压患者死亡率的关联》的信件的回应
Circ Res. 2020 Jun 5;126(12):e140-e141. doi: 10.1161/CIRCRESAHA.120.317205. Epub 2020 Jun 4.
3
Letter to the editors in response to: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic (Cure et al.).致编辑的信：回应《血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂在2019冠状病毒病大流行期间可能对糖尿病患者有害》（库尔等人）
Diabetes Metab Syndr. 2020 Jul-Aug;14(4):525-526. doi: 10.1016/j.dsx.2020.04.054. Epub 2020 May 5.
4
ACEing COVID-19: A Role for Angiotensin Axis Inhibition in SARS-CoV-2 Infection?对抗新冠病毒：血管紧张素轴抑制在新型冠状病毒感染中能发挥作用吗？
Circ Res. 2020 Jun 5;126(12):1682-1684. doi: 10.1161/CIRCRESAHA.120.317174. Epub 2020 Apr 17.
5
Renin-angiotensin-aldosterone system inhibitors to treat COVID-19?肾素-血管紧张素-醛固酮系统抑制剂用于治疗新型冠状病毒肺炎？
CMAJ. 2020 Jun 29;192(26):E728. doi: 10.1503/cmaj.76023.
6
Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality.血管紧张素转换酶（ACE）抑制剂与血管紧张素II受体阻滞剂对2019冠状病毒病死亡风险的比较影响
Hypertension. 2020 Aug;76(2):e15-e17. doi: 10.1161/HYPERTENSIONAHA.120.15622. Epub 2020 Jun 3.
7
COVID-19 and cardiovascular comorbidities: An update.新型冠状病毒肺炎与心血管合并症：最新进展
Rev Port Cardiol (Engl Ed). 2020 Aug;39(8):417-419. doi: 10.1016/j.repc.2020.06.013. Epub 2020 Jul 9.
8
Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus.血管紧张素转换酶抑制剂、血管紧张素 II 受体阻滞剂与冠状病毒
J Hypertens. 2020 Jun;38(6):1190-1191. doi: 10.1097/HJH.0000000000002469.
9
Letter to the editor: The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in developing a COVID-19 comorbidity-based host risk score.致编辑的信：血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂在基于新冠病毒疾病合并症的宿主风险评分制定中的作用
Crit Care. 2020 May 19;24(1):242. doi: 10.1186/s13054-020-02903-9.
10
Coronavirus disease 2019 (COVID-19): angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and cardiovascular disease.2019冠状病毒病（COVID-19）：血管紧张素转换酶抑制剂、血管紧张素II受体阻滞剂与心血管疾病
Med J Aust. 2020 Jun;212(11):502-503.e1. doi: 10.5694/mja2.50622. Epub 2020 May 21.
引用本文的文献
1
Outcome of COVID-19 infection in patients on antihypertensives: A cross-sectional study.高血压患者感染新型冠状病毒肺炎的结局：一项横断面研究。
World J Crit Care Med. 2024 Sep 9;13(3):96882. doi: 10.5492/wjccm.v13.i3.96882.
2
The possible mechanism and research progress of ACE2 involved in cardiovascular injury caused by COVID-19: a review.血管紧张素转换酶2（ACE2）参与新型冠状病毒肺炎（COVID-19）所致心血管损伤的可能机制及研究进展：综述
Front Cardiovasc Med. 2024 May 27;11:1409723. doi: 10.3389/fcvm.2024.1409723. eCollection 2024.
3
COVID-19 and cardiovascular comorbidities: An update.新型冠状病毒肺炎与心血管合并症：最新进展
Rev Port Cardiol (Engl Ed). 2020 Aug;39(8):417-419. doi: 10.1016/j.repce.2020.06.002. Epub 2020 Dec 16.
4
Phenome-wide association study and precision medicine of cardiovascular diseases in the post-COVID-19 era.后 COVID-19 时代心血管疾病的表型全基因组关联研究和精准医学。
Acta Pharmacol Sin. 2023 Dec;44(12):2347-2357. doi: 10.1038/s41401-023-01119-1. Epub 2023 Aug 2.
5
An update from the Canadian Association for the Study of the Liver on the management of liver disease during the COVID-19 pandemic.加拿大肝脏研究协会关于2019冠状病毒病大流行期间肝病管理的最新情况。
Can Liver J. 2020 Nov 17;3(4):309-321. doi: 10.3138/canlivj-2020-0013. eCollection 2020 Fall.
6
From COVID-19 to Sarcoidosis: How Similar Are These Two Diseases?从 COVID-19 到结节病：这两种疾病有多相似？
Front Immunol. 2022 May 9;13:877303. doi: 10.3389/fimmu.2022.877303. eCollection 2022.
7
Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest Physicians.SARS-CoV-2 大流行背景下慢性呼吸道疾病患者的风险评估：德国呼吸学会与德国胸科医师协会支持的立场声明。
Respiration. 2022;101(3):307-320. doi: 10.1159/000518896. Epub 2022 Jan 21.
8
Relationship Between Blood Lipid Levels and Mortality in Hospitalized COVID-19 Patients.住院 COVID-19 患者的血脂水平与死亡率的关系。
Angiology. 2022 Sep;73(8):724-733. doi: 10.1177/00033197211072346. Epub 2022 Feb 6.
9
Effect of Angiotensin-Converting-Enzyme Inhibitor and Angiotensin II Receptor Antagonist Treatment on ACE2 Expression and SARS-CoV-2 Replication in Primary Airway Epithelial Cells.血管紧张素转换酶抑制剂和血管紧张素II受体拮抗剂治疗对原代气道上皮细胞中ACE2表达及新型冠状病毒复制的影响
Front Pharmacol. 2021 Nov 19;12:765951. doi: 10.3389/fphar.2021.765951. eCollection 2021.
10
Molecular modeling of the interaction of ligands with ACE2-SARS-CoV-2 spike protein complex.配体与ACE2-SARS-CoV-2刺突蛋白复合物相互作用的分子模拟
In Silico Pharmacol. 2021 Oct 7;9(1):55. doi: 10.1007/s40203-021-00114-w. eCollection 2021.
本文引用的文献
1
Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study.美国退伍军人中按种族和民族划分的 COVID-19 检测和死亡率模式：一项全国性队列研究。
PLoS Med. 2020 Sep 22;17(9):e1003379. doi: 10.1371/journal.pmed.1003379. eCollection 2020 Sep.
2
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.在纽约市地区，5700 名因 COVID-19 住院的患者的特征、合并症和结局。
JAMA. 2020 May 26;323(20):2052-2059. doi: 10.1001/jama.2020.6775.
3
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.住院 COVID-19 合并高血压患者中血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的住院使用率与死亡率的关系。
Circ Res. 2020 Jun 5;126(12):1671-1681. doi: 10.1161/CIRCRESAHA.120.317134. Epub 2020 Apr 17.
4
Status of Hypertension in China: Results From the China Hypertension Survey, 2012-2015.中国高血压现状：2012-2015 年中国高血压调查结果。
Circulation. 2018 May 29;137(22):2344-2356. doi: 10.1161/CIRCULATIONAHA.117.032380. Epub 2018 Feb 15.
Zotero 插件